Catalog No.
DHD12603
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
scFv-kappa-heavy
Clonality
Monoclonal
Target
Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A
Concentration
2mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15692
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ESBA-1008, ESBA1008, RTH258, CAS: 1531589-13-5
Clone ID
Brolucizumab
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration, PMID: 30986442
Brolucizumab: First Approval, PMID: 31768932
Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration, PMID: 32107066
Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab, PMID: 32789284
Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration, PMID: 33197916
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial, PMID: 28551167
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab, PMID: 32344075
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration, PMID: 32574761
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER, PMID: 33207259
Brolucizumab-early real-world experience: BREW study, PMID: 32709960
Brolucizumab for macular degeneration, PMID: 32921890
Expert Opinion on Management of Intraocular Inflammation, Retinal Vasculitis, and Vascular Occlusion after Brolucizumab Treatment, PMID: 33007521
Is This a 737 Max Moment for Brolucizumab?, PMID: 32505363
Brolucizumab: the road ahead, PMID: 32829303
Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration, PMID: 32258827
Brolucizumab, PMID: 32105421
Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world, PMID: 33082532
Brolucizumab and immunogenicity, PMID: 32251366
Brolucizumab as treatment of wet age-related maculopathy, PMID: 33332477
Pharmacoeconomic Report: Brolucizumab (Beovu): (Novartis Pharmaceuticals Canada Inc.) [Internet], PMID: 33347111
A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE), PMID: 32131127
Brolucizumab-another anti-VEGF or beyond, PMID: 32317791
Brolucizumab-key learnings from HAWK and HARRIER, PMID: 32203242
Brolucizumab (Beovu) for age-related macular degeneration, PMID: 32022789
Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations, PMID: 32280811
Retinal Vasculitis After Administration of Brolucizumab Resulting in Severe Loss of Visual Acuity, PMID: 32761135
Antibodies to watch in 2020, PMID: 31847708
Clinical Review Report: Brolucizumab (Beovu): (Novartis Pharmaceuticals Canada Inc.) [Internet], PMID: 33301280
Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD), PMID: 32132677
[Vaso-occlusive retinitis following intravitreal injection of brolucizumab], PMID: 33141333
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration, PMID: 31413539
Correction: Brolucizumab-early real-world experience: BREW study, PMID: 33323990
Brolucizumab: is extended VEGF suppression on the horizon?, PMID: 31527765
Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study, PMID: 33294727
CADTH Canadian Drug Expert Committee Recommendation: Brolucizumab (Beovu — Novartis Pharmaceuticals Canada Inc.): Indication: Treatment of neovascular (wet) age-related macular degeneration (nAMD) [Internet], PMID: 33301279
Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration, PMID: 33630045
Comment on: Is this a 737 Max Moment for Brolucizumab, PMID: 32948293
DLX1008 (brolucizumab), a single-chain anti-VEGF-A antibody fragment with low picomolar affinity, leads to tumor involution in an in vivo model of Kaposi Sarcoma, PMID: 32407363
Antibodies to watch in 2019, PMID: 30516432
[Intraocular inflammation with brolucizumab use : Patient management-diagnosis-therapy], PMID: 33555415
Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System, PMID: 30566697
Innovative therapies for neovascular age-related macular degeneration, PMID: 31298960
New therapeutic targets in the treatment of age-related macular degeneration, PMID: 31787390
Reply to Comment on: Is this a 737 Max Moment for Brolucizumab?, PMID: 33187630
Drugs for common eye disorders, PMID: 31770361
Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data, PMID: 32065533
Gene, Cell and Antibody-Based Therapies for the Treatment of Age-Related Macular Degeneration, PMID: 32982165
Brolucizumab: a novel anti-VEGF humanized single-chain antibody fragment for treating w-AMD, PMID: 33899632
Advanced Coats' disease treated with intravitreal brolucizumab combined with laser photocoagulation, PMID: 32671288
Emerging therapies in the management of macular edema: a review, PMID: 31448093
For research use only. Not for human or drug use.
